全文获取类型
收费全文 | 1456篇 |
免费 | 212篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 165篇 |
妇产科学 | 37篇 |
基础医学 | 148篇 |
口腔科学 | 78篇 |
临床医学 | 197篇 |
内科学 | 306篇 |
皮肤病学 | 10篇 |
神经病学 | 96篇 |
特种医学 | 172篇 |
外科学 | 217篇 |
综合类 | 39篇 |
预防医学 | 56篇 |
眼科学 | 3篇 |
药学 | 34篇 |
中国医学 | 5篇 |
肿瘤学 | 100篇 |
出版年
2023年 | 7篇 |
2022年 | 4篇 |
2021年 | 17篇 |
2020年 | 11篇 |
2019年 | 9篇 |
2018年 | 46篇 |
2017年 | 52篇 |
2016年 | 40篇 |
2015年 | 43篇 |
2014年 | 42篇 |
2013年 | 73篇 |
2012年 | 43篇 |
2011年 | 40篇 |
2010年 | 71篇 |
2009年 | 58篇 |
2008年 | 46篇 |
2007年 | 42篇 |
2006年 | 40篇 |
2005年 | 32篇 |
2004年 | 32篇 |
2003年 | 30篇 |
2002年 | 27篇 |
2001年 | 30篇 |
2000年 | 14篇 |
1999年 | 19篇 |
1998年 | 63篇 |
1997年 | 55篇 |
1996年 | 63篇 |
1995年 | 56篇 |
1994年 | 37篇 |
1993年 | 46篇 |
1992年 | 45篇 |
1991年 | 42篇 |
1990年 | 55篇 |
1989年 | 33篇 |
1988年 | 45篇 |
1987年 | 36篇 |
1986年 | 33篇 |
1985年 | 22篇 |
1984年 | 24篇 |
1983年 | 28篇 |
1982年 | 14篇 |
1981年 | 24篇 |
1980年 | 17篇 |
1979年 | 12篇 |
1978年 | 18篇 |
1977年 | 15篇 |
1976年 | 12篇 |
1975年 | 5篇 |
1971年 | 2篇 |
排序方式: 共有1680条查询结果,搜索用时 15 毫秒
1.
Practical management of patients with non-small-cell lung cancer treated with gefitinib. 总被引:7,自引:0,他引:7
Neelam T Shah Mark G Kris William Pao Leslie B Tyson Barbara M Pizzo Murk-Hein Heinemann Leah Ben-Porat Dana L Sachs Robert T Heelan Vincent A Miller 《Journal of clinical oncology》2005,23(1):165-174
PURPOSE: The use of gefitinib, the first drug approved to inhibit the epidermal growth factor receptor tyrosine kinase, is indicated in patients with non-small-cell lung cancer with tumors progressive after chemotherapy. The unique mechanism of action of this agent leads to distinctive patterns of response and toxicity in persons with lung cancer. Many of the principles of management relevant to gefitinib are distinct from those with conventional cytotoxic drugs. To meet this need, we present practical guidelines on the use of gefitinib in patients with non-small-cell lung cancer. METHODS: This article reviews gefitinib's indications, dosing, response phenomena, and patterns of relapse in individuals with radiographic response. RESULTS: We present our recommendations for the management of rash and diarrhea caused by this agent. CONCLUSION: This information can guide practitioners and help them inform their patients about what to expect when they receive gefitinib. 相似文献
2.
Serum and Cerebrospinal Fluid Pharmacokinetics of Intravenous and Oral Lamivudine in Human Immunodeficiency Virus-Infected Children 总被引:3,自引:3,他引:0 下载免费PDF全文
Brigitta U. Mueller Linda L. Lewis Geoffrey J. Yuen Maureen Farley Amy Keller Joseph A. Church Jonathan C. Goldsmith David J. Venzon Marc Rubin Philip A. Pizzo Frank M. Balis 《Antimicrobial agents and chemotherapy》1998,42(12):3187-3192
We studied the pharmacokinetics of intravenously and orally administered lamivudine at six dose levels ranging from 0.5 to 10 mg/kg of body weight in 52 children with human immunodeficiency virus infection. A two-compartment model with first-order elimination from the central compartment was simultaneously fitted to the serum drug concentration-time data obtained after intravenous and oral administration. The maximal concentration at the end of the 1-h intravenous infusion and the area under the concentration-time curve after oral and intravenous administration increased proportionally with the dose. The mean clearance of lamivudine (± standard deviation) in the children was 0.53 ± 0.19 liter/kg/h (229 ± 77 ml/min/m2 of body surface area), and the mean half-lives at the distribution and elimination phases were 0.23 ± 0.18 and 2.2 ± 2.1 h, respectively. Clearance was age dependent when normalized to body weight but age independent when normalized to body surface area. Lamivudine was rapidly absorbed after oral administration, and 66% ± 25% of the oral dose was absorbed. Serum lamivudine concentrations were maintained above 1 μM for ≥8 h of 24 h on the twice daily oral dosing schedule with doses of ≥2 mg/kg. The cerebrospinal fluid drug concentration measured 2 to 4 h after the dose was 12% (range, 0 to 46%) of the simultaneously measured serum drug concentration. A limited-sampling strategy was developed to estimate the area under the concentration-time curve for concentrations in serum at 2 and 6 h. 相似文献
3.
Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand
PA Crock JD McKenzie AM Nicoll NJ Howard W Cutfield LK Shield G Byrne 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(4):381-386
Benign intracranial hypertension (BIH) is reported in three children from Australia and one from New Zealand, who were being treated with recombinant human growth hormone (rhGH). Three males and one female, aged between 10.5 and 14.2 y, developed intracranial hypertension within 2 weeks to 3 months of starting treatment. A national database, OZGROW, has been prospectively collecting data on all 3332 children treated with rhGH in Australia and New Zealand from January 1986 to 1996. The incidence of BIH in children treated with growth hormone (GH) is small, 1.2 per 1000 cases overall, but appears to be greater with biochemical GHD (<10IUml -1 ), i.e. 6.5/1000 (3 in 465 cases), relative risk 18.4, 95% confidence interval 1.9-176.1, than in all other children on the database. The incidence in patients with Turner's syndrome was 2.3/1000 (1 in 428 cases). No cases in patients with partial GHD (10–20 IUml -1 ) or chronic renal failure were identified. Possible causative mechanisms are discussed. The authors'practice is now to start GH replacement at less than the usual recommended dose of 14IUm-2 week-1 in those children considered to be at high risk of developing BIH. Ophthalmological evaluation is recommended for children before and during the first few months following commencement of rhGH therapy and is mandatory in the event of peripheral or facial oedema, persistent headaches, vomiting or visual symptoms. The absence of papilledema does not exclude the diagnosis. 相似文献
4.
Hand-assisted laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma. 总被引:1,自引:0,他引:1
Jay D Raman Michael A Palese Casey K Ng Stephen A Boorjian Douglas S Scherr Joseph J Del Pizzo R Ernest Sosa 《JSLS, Journal of the Society of Laparoendoscopic Surgeons》2006,10(4):432-438
OBJECTIVE: We report our experience with hand-assisted laparoscopic nephroureterectomy (HALN) for upper urinary tract transitional cell carcinoma and compare our results with a contemporary series of open nephroureterectomy (ON) performed at our institution. METHODS: Between August 1996 and May 2003, 90 patients underwent nephroureterectomy for upper-tract transitional cell carcinoma (TCC). Thirty-eight patients underwent HALN, while 52 had an ON. End-points of comparison included operative time, estimated blood loss (EBL), intraoperative and postoperative complications, length of hospital stay, pathologic grade and stage of tumor, and tumor recurrence. RESULTS: The mean patient age was 72.3 and 70.6 years in the ON and HALN groups, respectively. Mean operative duration was 243 minutes (ON) and 244 minutes (HALN), with an EBL of 478mL in the open group versus 191 mL in the hand-assisted group (P<0.001). No intraoperative complications occurred, but postoperative complications occurred in 4% and 11% of the ON and HALN groups, respectively (P=0.21). The mean hospital duration was 7.1 days (ON) versus 4.6 days (HALN) (P<0.01). No difference existed in the pathologic grade or stage distribution of urothelial tumors between the 2 groups. The mean follow-up was 51.0 months in the ON group and 31.7 months in the HALN group. Recurrence of urothelial carcinoma occurred in 50% of patients who underwent ON and 40% treated by HALN (P=0.38) at a median interval of 9.1 and 7.7 months, respectively, after surgery. CONCLUSION: Hand-assisted laparoscopic nephroureterectomy is an effective modality for the treatment of upper urinary tract urothelial carcinoma. Patients benefited from less intraoperative blood loss and a shorter hospitalization with an equivalent intermediate-term oncologic outcome compared with that of the open approach. 相似文献
5.
In a prospective, randomized, double-blind study, 49 patients underwent lumbar myelography using iotrol (24 patients) or metrizamide (25 patients). The diagnostic imaging adequacy of iotrol was comparable with that of metrizamide. After iotrol myelography, adverse reactions were fewer, less severe, and of shorter duration than were those following metrizamide myelography. Thirteen of 24 patients (54%) receiving iotrol reported some adverse reactions compared with 24 of 25 patients (96%) receiving metrizamide. Five moderate and one severe adverse reaction occurred in the group receiving iotrol. Fourteen moderate and eight severe adverse reactions occurred in the group receiving metrizamide. Thirty-eight patients underwent electroencephalography both before and after myelography (19 iotrol and 19 metrizamide). None of the EEGs obtained after iotrol myelography changed from baseline, while seven of the EEGs obtained after metrizamide myelography showed changes from baseline. Iotrol was judged superior to metrizamide as a contrast medium in this patient population. 相似文献
6.
7.
8.
9.
10.